Severe Cdiff? May try tigecycline

By  |  June 23, 2009 | 

In this small case series of 4 patients in shock due to Cdiff (refractory to metronidazole and vancomycin), all had clinical and microbiologic cure (without recurrence) after treatment with tigecycline. Tigecycline does not induce proliferation of the Cdiff organism or the toxin production. Although premature for widespread use, it may be a reasonable alternative for septic patients that have failed traditional treatment options, and are headed for colectomy (abstract).

Leave A Comment

About the Author:

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Categories

Related Posts

By  | June 29, 2013 |  0
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
By  | June 22, 2013 |  0
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
By  | May 25, 2013 |  0
This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]